A Study for Expanding Application Sites for Rotigotine Transdermal Patch
The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD). Some PD patients cannot continue RTP treatment due to application site reactions. We explored sites for RTP where application site reactions are less severe than those in the six approved application...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2020/5892163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172336751247360 |
|---|---|
| author | Hitoshi Kujirai Sakiko Itaya Yumi Ono Makoto Takahashi Akira Inaba Yasushi Shimo Nobutaka Hattori Satoshi Orimo |
| author_facet | Hitoshi Kujirai Sakiko Itaya Yumi Ono Makoto Takahashi Akira Inaba Yasushi Shimo Nobutaka Hattori Satoshi Orimo |
| author_sort | Hitoshi Kujirai |
| collection | DOAJ |
| description | The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD). Some PD patients cannot continue RTP treatment due to application site reactions. We explored sites for RTP where application site reactions are less severe than those in the six approved application sites. Thirty PD patients (12 men, mean age = 76 years) who underwent RTP at the approved sites and had some application site reactions were enrolled in this study. When applying the RTP to the approved application sites for more than four weeks (pre-RTP) and then on the shin for the following four weeks (post-RTP), skin reactions, itching evaluated using the skin irritation score, motor symptoms, clinical global impressions scale, and plasma rotigotine concentration were examined. The mean visual analogue scale and skin irritation score in the post-RTP group were significantly lower than those in the pre-RTP group. The mean Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III score in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. Plasma rotigotine concentration in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. These results indicate that the shin can be a useful application site for RTP. |
| format | Article |
| id | doaj-art-cf8c40ebc1c34c71a1c921944afce1ea |
| institution | OA Journals |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-cf8c40ebc1c34c71a1c921944afce1ea2025-08-20T02:20:06ZengWileyParkinson's Disease2090-80832042-00802020-01-01202010.1155/2020/58921635892163A Study for Expanding Application Sites for Rotigotine Transdermal PatchHitoshi Kujirai0Sakiko Itaya1Yumi Ono2Makoto Takahashi3Akira Inaba4Yasushi Shimo5Nobutaka Hattori6Satoshi Orimo7Department of Neurology, Kanto Central Hospital, Tokyo 158-8531, JapanDepartment of Neurology, Kanto Central Hospital, Tokyo 158-8531, JapanSchool of Computing, Tokyo Institute of Technology, Tokyo, Kanagawa 226-8503, JapanDepartment of Neurology, Kanto Central Hospital, Tokyo 158-8531, JapanDepartment of Neurology, Kanto Central Hospital, Tokyo 158-8531, JapanDepartment of Neurology, Juntendo University School of Medicine, Tokyo 113-8421, JapanDepartment of Neurology, Juntendo University School of Medicine, Tokyo 113-8421, JapanDepartment of Neurology, Kanto Central Hospital, Tokyo 158-8531, JapanThe rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD). Some PD patients cannot continue RTP treatment due to application site reactions. We explored sites for RTP where application site reactions are less severe than those in the six approved application sites. Thirty PD patients (12 men, mean age = 76 years) who underwent RTP at the approved sites and had some application site reactions were enrolled in this study. When applying the RTP to the approved application sites for more than four weeks (pre-RTP) and then on the shin for the following four weeks (post-RTP), skin reactions, itching evaluated using the skin irritation score, motor symptoms, clinical global impressions scale, and plasma rotigotine concentration were examined. The mean visual analogue scale and skin irritation score in the post-RTP group were significantly lower than those in the pre-RTP group. The mean Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III score in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. Plasma rotigotine concentration in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. These results indicate that the shin can be a useful application site for RTP.http://dx.doi.org/10.1155/2020/5892163 |
| spellingShingle | Hitoshi Kujirai Sakiko Itaya Yumi Ono Makoto Takahashi Akira Inaba Yasushi Shimo Nobutaka Hattori Satoshi Orimo A Study for Expanding Application Sites for Rotigotine Transdermal Patch Parkinson's Disease |
| title | A Study for Expanding Application Sites for Rotigotine Transdermal Patch |
| title_full | A Study for Expanding Application Sites for Rotigotine Transdermal Patch |
| title_fullStr | A Study for Expanding Application Sites for Rotigotine Transdermal Patch |
| title_full_unstemmed | A Study for Expanding Application Sites for Rotigotine Transdermal Patch |
| title_short | A Study for Expanding Application Sites for Rotigotine Transdermal Patch |
| title_sort | study for expanding application sites for rotigotine transdermal patch |
| url | http://dx.doi.org/10.1155/2020/5892163 |
| work_keys_str_mv | AT hitoshikujirai astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT sakikoitaya astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT yumiono astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT makototakahashi astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT akirainaba astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT yasushishimo astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT nobutakahattori astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT satoshiorimo astudyforexpandingapplicationsitesforrotigotinetransdermalpatch AT hitoshikujirai studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT sakikoitaya studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT yumiono studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT makototakahashi studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT akirainaba studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT yasushishimo studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT nobutakahattori studyforexpandingapplicationsitesforrotigotinetransdermalpatch AT satoshiorimo studyforexpandingapplicationsitesforrotigotinetransdermalpatch |